|1.||Puri, Raj K: 5 articles (04/2012 - 10/2003)|
|2.||Reynolds, Paul R: 4 articles (10/2014 - 05/2010)|
|3.||Husain, Syed R: 4 articles (04/2012 - 10/2003)|
|4.||Lam, Kit S: 4 articles (09/2007 - 01/2002)|
|5.||Liu, Ruiwu: 4 articles (09/2007 - 05/2005)|
|6.||Marik, Jan: 4 articles (09/2007 - 05/2005)|
|7.||Varesio, Luigi: 3 articles (10/2014 - 03/2011)|
|8.||Bosco, Maria Carla: 3 articles (10/2014 - 03/2011)|
|9.||Marks, James D: 3 articles (10/2012 - 01/2010)|
|10.||Hall, Walter A: 3 articles (10/2011 - 08/2003)|
06/01/2011 - "Developments are currently being undertaken that aim to provide improved imaging methods for the detection and evaluation of tumors, for identifying important characteristics of tumors such as the expression levels of cell surface receptors that may dictate what types of therapy will be effective and for evaluating their response to treatments. "
07/15/2002 - "The permanent genetic programming via gene transfer of autologous T cells with cell surface receptors directed toward tumor-related Ags holds great promise for the development of more-specific tumor therapies. "
07/21/2014 - "This strategy is also a cost-effective and convenient operation, implying great promise for the sensitive recognition of cancer cells and cell surface receptors; thus, it is helpful in cancer diagnosis. "
05/01/2010 - "This strategy offers great promise for sensitive detection of cancer cells and cell surface receptors and thus may help improve cancer diagnosis and treatment."
01/01/1996 - "Control Group concentrations of sIL-2R were in the range of 101.9 to 255.3 IU/mL with a mean value of 178.6 IU/mL. Serum levels of sIL-2R were markedly elevated in the sera of children with solid tumors (Study Group) to levels between 223.8 IU/mL and 927 IU/mL with a mean value of 575.4 IU/mL. 1) The shedding of cell-surface receptors of immunological effector cells is a common physiological mechanism; 2) Presence of sIL-2R represents a sign of an overall activation of the effector elements of the host's cellular immune system; 3) An increase in the levels of sIL-2R represents an active phase of progression; conversely, decreasing levels indicate tumor regression; 4) Serum levels of sIL-2Rs may represent a useful laboratory parameter in choosing an efficient anti-cancer therapy. "
09/08/2015 - "The (EGFpep+Tfpep)-AuNPs-Pc 4 with a particle size of ∼41 nm improved both specificity and worked synergistically to decrease time of maximal accumulation in human glioma cells that overexpressed two cell surface receptors as compared to cells that overexpressed only one. "
10/01/2011 - "We also summarize the clinical trials of drugs targeting these cell surface receptors in malignant glioma patients."
10/01/2011 - "Here, we review these common cell surface receptors with clinical significance for malignant glioma and discuss the molecular characteristics, pathological significance, and potential therapeutic application of these cell surface receptors. "
10/01/2011 - "Cell surface receptors in malignant glioma."
05/01/2002 - "We therefore sought to determine which glioma cell surface receptors or components of the extracellular matrix in gliomas influenced DC viability. "
07/01/1981 - "Eight spontaneous thymic lymphomas from AKR mice were characterized individually in vitro for cell surface receptors and mitogen reactivity. "
07/01/1981 - "Heterogeneity of cell surface receptors and mitogen reactivity of individual spontaneous AKR lymphomas."
05/22/1980 - "A prediction of the hypothesis is that T-lymphoma proliferation is dependent on continued presentation of MuLV envelope determinants to these cell-surface receptors, and that substances which interfere with receptor-virus interactions should inhibit T-lymphoma proliferation. "
05/01/1979 - "We conclude that the presence of specific cell surface receptors for lymphoma cell-produced and recombinant AKR retroviruses is a marker for leukemia in these hosts."
12/01/1995 - "The signal may be predictive of the efficacy of treatment with synthetic peptide ligands and may be useful in the evaluation of ligands for other cell surface receptors with biological effects on B-lymphoma cells."
|4.||Melanoma (Melanoma, Malignant)
01/01/2007 - "Fluorescence microscopy is subsequently utilized to examine the targeting capabilities of peptide-amphiphile LUVs, which should allow for improved drug selectivity towards melanoma vs normal cells based on differences in the relative abundance of the targeted cell surface receptors."
12/01/2013 - "Our results show that GlcNAc β1,6 N-glycosylation of cell surface receptors, which increases with the aggressiveness of melanoma cells, is an important factor influencing melanoma cell migration. "
06/01/1991 - "Human melanocyte strains and melanoma cell lines have been characterised with regard to levels of cell surface receptors of the integrin family. "
01/01/2014 - "These enzymes not only remodel the extracellular matrix, but also release active factors and shed cell surface receptors thereby mediating melanoma cross-communication with their microenvironment. "
06/01/2005 - "CDK activity is sustained in melanoma cells mostly by the elimination of the CDK inhibitor p16INK4A and by high levels of cyclins whose expression is maintained by stimuli emanating from activated cell surface receptors and/or mutated intracellular intermediates, such as N-Ras and B-Raf. "
|5.||Glioblastoma (Glioblastoma Multiforme)
01/01/2010 - "Sensing invasion: cell surface receptors driving spreading of glioblastoma."
02/01/2002 - "Expression of Cell Surface Receptors on Human Glioblastoma Xenograft Model in NOD/SCID Mouse."
12/01/2013 - "Among many cell surface receptors, members of the integrin family are known to regulate glioblastoma cell invasion in concert with extracellular matrix degrading proteases. "
02/01/2002 - "To obtain basic data for development of a glioblastoma-specific immunotoxin, the expression of variable cell surface receptors on a human glioblastoma xenograft model was evaluated, using NOD/SCID mice. "
05/01/2012 - "As we and others have shown, human gliomas, especially glioblastoma, express all PDGF ligands and both the two cell surface receptors, PDGFR-α and -β. "
|3.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Interleukin-1 (Interleukin 1)
|1.||Drug Therapy (Chemotherapy)
|5.||Heterologous Transplantation (Xenotransplantation)